Skip to main content
. 2024 Oct 30;16(10):6483–6495. doi: 10.21037/jtd-24-940

Table 2. Tumor response in patients with advanced NSCLC receiving S-1 as second-line or later therapy.

Items Total (n=52), n (%)
PR 15 (28.8)
SD 20 (38.5)
PD 17 (32.7)
ORR 15 (28.8)
DCR 35 (67.3)

NSCLC, non-small cell lung cancer; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.